ClinicalTrials.gg
Active, not recruitingNCT06921486Updated Jan 30, 2026

The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)

A Phase 2/3 interventional study of Phase IIb:Efsubaglutide Alfa 5 mg QW and Phase IIb:Efsubaglutide Alfa 10 mg QW in Obesity and Overweight, sponsored by Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.. Active, not recruiting at 41 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,003
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 603 studies in Obesity with a site in China — 223 open to participants now, 284 under way, 67 of them phase 3. Obesity · China.

Enrollment
32nd of 504
1,003 · median 120
Started
2025
with 114 others
Phase 2/3
8 of 603
2 open now
Primary completion
2026-08
later than 77 of 282 live
Registered
338th of 603
by date

Among the 603 studies in Obesity with a site in China, this one is the 32nd largest by enrollment of the 504 interventional ones that give a count, is one of 115 that started in 2025, is one of 8 in phase 2/3, reaches primary completion later than 77 of the 282 other live ones, and was the 338th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

223 of the 603 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

218 more — sign in →

All 223 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 603 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, double-blind, placebo-controlled Phase IIb/III clinical trial aimed at evaluating the efficacy, safety, pharmacokinetics (PK), and immunogenicity profile of Efsubaglutide Alfa injection in overweight and obese subjects. The primary endpoint of the Phase IIb is the percentage change in body weight from baseline after 18 weeks of treatment. The primary endpoint of the Phase III is the percentage change in body weight from baseline after 30 weeks of treatment, the secondary endpoint is the percentage change in body weight from baseline after a cumulative 48 weeks of treatment.

03

Conditions studied

  • Obesity and Overweight
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in the clinical study; fully understand and be informed about the study, and sign the form (ICF); willing to follow and capable of completing all study procedures.
  2. Age ≥ 18 years (including the cutoff value, based on the time of signing the ICF), regardless of gender.
  3. History of poor weight control through diet and exercise [defined as weight control failure if the subject has attempted at least 3 months of diet and exercise alone prior to screening without achieving a weight loss of ≥ 5.0% (based on subject self-report)].
  4. Willing to follow the recommendations of the investigator regarding medication, diet, and exercise.
  5. Stable weight within 3 months prior to screening (defined as a weight change \< 5%, based on subject self-report).
  6. Obesity: (BMI) ≥ 28 kg/m² (including the cutoff value) with or without comorbidities; or overweight: BMI ≥ 24 and \< 28 kg/m² with at least one weight-related comorbidity, including but not limited to prediabetes (impaired fasting glucose [FPG] and/or abnormal glucose tolerance), hypertension, dyslipidemia, non-alcoholic fatty liver disease, or obstructive sleep apnea syndrome.
  7. Women of must have a negative blood pregnancy test during the screening period. Women of childbearing potential or male subjects and their partners must agree not to plan for pregnancy from the time of signing the ICF until 3 months after the last dose of the drug, and voluntarily agree to use effective , with no plans for sperm or egg donation.

Exclusion criteria

Exclusion Criteria:

  1. Allergic constitution or allergic to any component of the drug.
  2. Previously treated with Efsubaglutide Alfa injection.
  3. Received glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, insulin, metformin, insulin secretagogues, or thiazolidinediones (TZD) or any other weight-affecting anti-diabetic medication within the past 3 months before screening.
  4. ≥ 6.5% at screening, or previously diagnosed with Type 1 or Type 2 diabetes (based on the World Health Organization [WHO] 2020 diabetes diagnosis and classification standards).
  5. History of severe hypoglycemia or recurrent symptomatic hypoglycemia (≥ 2 times in the past 6 months).
  6. Known single-gene mutations, other diseases, or drug-induced obesity, including but not limited to hypothalamic obesity, pituitary obesity, hypothyroid obesity, Cushing's syndrome, insulinoma, growth hormone deficiency, acromegaly, pseudohypoparathyroidism, gonadal dysfunction, etc.
  7. gastric emptying abnormalities (e.g., gastric outlet obstruction), severe chronic gastrointestinal diseases (e.g., active ulcers in the past 6 months), long-term use of drugs directly affecting gastrointestinal motility (including but not limited to mosapride, cisapride, etc.), or having undergone gastrointestinal surgery within the past 6 months and deemed unsuitable for participation by the investigator.
  8. Use of weight-affecting medications within 3 months prior to screening, including tricyclic antidepressants, psychiatric medications, or sedative drugs (such as imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, sulpiride, clozapine, olanzapine, valproic acid, valproic acid derivatives, lithium salts, etc.). Note: Excluded if cumulative or continuous systemic use is less than 14 days.
  9. Use of non-prescription weight loss medications or appetite suppressants (including traditional Chinese medicine weight loss drugs) within 1 month prior to screening, or use of prescription weight loss medications (e.g., phentermine, sibutramine, orlistat) or lipid-dissolving injectables (e.g., lipolytic injections) within 3 months prior to screening.
  10. Previously underwent weight-loss surgery (excluding acupuncture, liposuction, and abdominal fat removal within 1 year before screening), or plans to undergo surgery for obesity during the study period, such as gastric bypass surgery or gastric band surgery.
  11. Currently on a weight loss plan and not in the maintenance phase.
  12. History of hyperthyroidism or hypothyroidism, or thyroid-stimulating hormone (TSH) \< 1×LLN (lower limit of normal) or TSH > 1.5× (upper limit of normal).
  13. Screening serum calcitonin ≥ 50 ng/L (or ≥ 50 pg/mL), or history of medullary thyroid cancer, multiple endocrine neoplasia (MEN) syndrome type 2A or 2B, or related family history (family history defined as a first-degree relative with the disease).
  14. History of acute or chronic pancreatitis, cholecystectomy, or symptomatic gallbladder disease (patients with post-surgery resolved gallstones or cholecystectomy without sequelae can be enrolled), or known history of pancreatic injury or high-risk factors for pancreatitis, or screening with serum amylase or lipase > 2×ULN.
  15. Any disease that could affect HbA1c measurement, such as hemolytic anemia, sickle cell disease, etc.
  16. Currently receiving or have received chronic (> 14 days) systemic corticosteroid treatment in the past 3 months (excluding local, intraocular, intranasal, intra-articular, or inhaled formulations), or have evidence of severe, active disorders (e.g., lupus or rheumatoid arthritis), and, in the opinion of the investigator, require or may require systemic corticosteroid treatment within the next 12 months.
  17. History of within 5 years prior to screening, excluding clinically cured cervical carcinoma in situ, squamous cell carcinoma of the skin, or basal cell carcinoma within the past 5 years.
  18. History of major surgery (e.g., thoracic, intracranial, or abdominal surgery) within 6 months prior to screening, or plans to undergo surgery that may affect study completion or adherence.
  19. Meets any of the following cardiac function criteria: clinically significant arrhythmias or conduction abnormalities requiring clinical intervention; hereditary long syndrome or QTcF > 450 msec or currently taking medications that may prolong the QT interval or cause torsades de pointes; clinically significant cardiovascular diseases, including acute myocardial infarction, unstable angina, coronary artery bypass graft surgery, (NYHA) class III or higher congestive heart failure, (LVEF) \< 50%, or uncontrolled hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg); other clinically significant cardiac abnormalities judged by the investigator.
  20. History of hemorrhagic or ischemic stroke or within 6 months prior to screening.
  21. Known infectious diseases: surface antigen (HBsAg) positive; virus (HCV) antibody positive and HCV RNA above the detection limit; (HIV) antibody positive; Treponema pallidum antibody positive.
  22. Laboratory findings meeting any of the following: (ALT) ≥ 3.0×ULN (subjects diagnosed with non-alcoholic fatty liver disease during screening and within the past 6 months with ALT ≤ 5.0×ULN may be enrolled); aspartate aminotransferase (AST) ≥ 3.0×ULN; total (TBIL) ≥ 2.0×ULN; estimated (eGFR) \< 60 mL/min/1.73 m² (CKD-EPI formula); fasting triglycerides (TG) > 5.65 mmol/L.
  23. Known or suspected alcohol abuse within 1 year prior to screening (defined as male subjects consuming > 24 g alcohol per day, female subjects consuming > 12 g alcohol per day; 12 g alcohol is approximately equivalent to 300 mL beer, 100 mL wine, or 25 mL spirits).
  24. Known or suspected drug abuse at screening.
  25. Pregnant or breastfeeding women.
  26. History of moderate to severe depression, anxiety, or serious mental disorders, such as schizophrenia, bipolar disorder, etc., or screening PHQ-9 score ≥ 15.
  27. History of suicidal tendencies or suicide attempts.
  28. Participation in a clinical trial involving vaccines, medical devices, or other drugs within 3 months prior to screening (except for observational studies).
  29. The investigator or treating physician considers that the subject has any factors that may affect the evaluation of the efficacy or safety of the study, and is deemed unsuitable for participation in the study.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,003 participants (actual)

Study arms

  • Experimental
    Phase IIb:Efsubaglutide Alfa 5 mg QW

    The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg, reaching the target dose of 5 mg at Week 3 (W3). From W3 to W18, the treatment is maintained at a 5 mg dose.

    Drug: Phase IIb:Efsubaglutide Alfa 5 mg QW

  • Experimental
    Phase IIb:Efsubaglutide Alfa 10 mg QW

    The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg, reaching the target dose of 10 mg at Week 5 (W5). From W5 to W18, the treatment is maintained at a 10 mg dose.

    Drug: Phase IIb:Efsubaglutide Alfa 10 mg QW

  • Experimental
    Phase IIb:Efsubaglutide Alfa 20 mg QW

    The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 mg, reaching the target dose of 20 mg at Week 7 (W7). From W7 to W18, the treatment is maintained at a 20 mg dose.

    Drug: Phase IIb:Efsubaglutide Alfa 20 mg QW

  • Experimental
    Phase IIb:Efsubaglutide Alfa 20 mg Q2W

    From Week 1 (W1) to Week 6 (W6), the drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 mg, reaching the target dose of 20 mg at Week 7 (W7). From W7 to W18, the drug is administered every two weeks and maintained at a 20 mg dose.

    Drug: Phase IIb:Efsubaglutide Alfa 20 mg Q2W

  • Placebo comparator
    Phase IIb:Placebo

    Once weekly

    Drug: Phase IIb:Placebo

  • Experimental
    Phase III:Recommended Phase 3 Dose (RP3D) Low Dose QW

    The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 mg, The dose escalation continues until reaching the RP3D Low Dose, and then the RP3D is maintained. The total cumulative duration of drug administration (from the first dose to the end of maintenance) is 48 weeks, with the once-weekly administration frequency retained throughout the entire period.

    Drug: Phase III:Recommended Phase 3 Dose Low Dose

  • Experimental
    Phase III:Recommended Phase 3 Dose (RP3D) High Dose QW

    The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 mg, The dose escalation continues until reaching the RP3D High Dose, and then the RP3D is maintained. The total cumulative duration of drug administration (from the first dose to the end of maintenance) is 48 weeks, with the once-weekly administration frequency retained throughout the entire period.

    Drug: Phase III:Recommended Phase 3 Dose High Dose

  • Experimental
    Phase III:Recommended Phase 3 Dose (RP3D) High Dose Q2W

    The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence: 1 mg → 5 mg → 10 mg → 20 mg. Dose escalation continues until reaching the RP3D High Dose. Once the RP3D High Dose is achieved, the treatment regimen transitions to alternating weekly between RP3D High Dose and placebo for the remainder of the study. The total cumulative duration of drug administration (from the first dose to the end of the maintenance phase) remains 48 weeks, with the once-weekly administration frequency retained throughout. Blinding is maintained across all treatment groups to ensure unbiased evaluation of efficacy and safety.

    Drug: Phase III:Recommended Phase 3 Dose High Dose · Drug: Phase III:Placebo

  • Placebo comparator
    Phase III:Placebo

    Once weekly

    Drug: Phase III:Placebo

Interventions

  • DrugPhase IIb:Efsubaglutide Alfa 5 mg QW

    IIb:Efsubaglutide Alfa 5 mg QW

  • DrugPhase IIb:Efsubaglutide Alfa 10 mg QW

    Efsubaglutide Alfa 10 mg QW

  • DrugPhase IIb:Efsubaglutide Alfa 20 mg QW

    Efsubaglutide Alfa 20 mg QW

  • DrugPhase IIb:Efsubaglutide Alfa 20 mg Q2W

    Efsubaglutide Alfa 20 mg Q2W

  • DrugPhase IIb:Placebo

    Placebo

  • DrugPhase III:Recommended Phase 3 Dose High Dose

    The Recommended Phase 3 Dose High Dose confirmed by the IDMC (Independent Data Monitoring Committee) based on the safety and efficacy data results from the 18-week Phase IIb.

  • DrugPhase III:Recommended Phase 3 Dose Low Dose

    The Recommended Phase 3 Dose Low Dose confirmed by the IDMC (Independent Data Monitoring Committee) based on the safety and efficacy data results from the 18-week Phase IIb.

  • DrugPhase III:Placebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Percentage change in body weight from baseline

    Time frame: Phase IIb (18 weeks) , Phase III (30 weeks)

  2. Proportion of subjects with ≥5% reduction in body weight from baseline

    Time frame: Phase III (30 weeks)

Secondary outcomes

  1. Proportion of subjects with ≥5% reduction in body weight from baseline

    Time frame: Phase IIb (18 weeks) , Phase III (48 weeks)

  2. Proportion of subjects with ≥10%, and ≥15% reduction in body weight from baseline

    Time frame: Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)

  3. Percentage change in body weight from baseline

    Time frame: Phase III (48 weeks)

  4. Change in body weight from baseline

    Time frame: Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)

  5. Change in BMI from baseline

    Time frame: Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)

  6. Change in waist circumference from baseline

    Time frame: Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)

  7. Change in hip circumference from baseline

    Time frame: Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)

  8. Change in blood pressure (diastolic and systolic) from baseline

    Time frame: Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)

  9. Change in lipid levels (triglycerides, total cholesterol, low-density lipoprotein cholesterol) from baseline, percentage change from baseline, and ratio to baseline.

    Time frame: Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)

  10. Change in blood glucose levels (FPG) from baseline

    Time frame: Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)

  11. Change in blood glucose levels (HbA1c) from baseline

    Time frame: Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)

  12. Change in blood glucose levels (fasting insulin) from baseline

    Time frame: Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)

  13. Change in blood glucose levels (insulin resistance index [HOMA-IR]) from baseline

    Time frame: Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)

  14. Change in blood uric acid levels from baseline

    Time frame: Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)

  15. Change in IWQOL-lite-CT (Impact of Weight on Quality of Life-Lite-Clinical Trial Version) Questionnaire Score from Baseline

    Time frame: Phase III (30 weeks and 48 weeks)

Other outcomes

  1. Change in Total Body Fat Mass from Baseline Measured by Dual-Energy X-ray Absorptiometry

    Time frame: Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)

  2. Change in Liver Fat Content (LFC) from Baseline Measured by MRI-PDFF

    Time frame: Phase IIb (18 weeks) , Phase III (30 weeks and 48 weeks)

  3. Change in Fibrosis-4 (FIB-4) Score from Baseline

    Time frame: Phase III (30 weeks and 48 weeks)

  4. Change in Nonalcoholic Fatty Liver Disease Fibrosis Score (NFS) from Baseline

    Time frame: Phase III (30 weeks and 48 weeks)

  5. Change in eGFR from Baseline

    Time frame: Phase III (30 weeks and 48 weeks)

  6. Change in Urinary Albumin-to-Creatinine Ratio (ACR) from Baseline

    Time frame: Phase III (30 weeks and 48 weeks)

07

Study locations

41 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Aug 2026, 17 months after the start.

Of 33 non-industry phase 2/3 interventional studies under Obesity, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 53. This study's planned 17 months is below that.

Counting every sponsor, half of 36 studies reached it within 47 months; a quarter within 30 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2025
First posted
Apr 10, 2025
StartActual
Mar 31, 2025
Primary completionEst.
Aug 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06921486
Lead sponsor
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Apr 10, 2025
Start date
Mar 31, 2025
Primary completion
Aug 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 30, 2026

Study contacts

Weiping Jia, M.D,Ph. D
principal investigator · Shanghai Jiao Tong University Affiliated Sixth People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion